Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study - Scorecard - MDSpire
Advertisement
Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study
Clinical Scorecard: Efficacy and Safety of Dupilumab in Young Children (≤6 Years) with Uncontrolled Persistent Asthma: A Retrospective Cohort Analysis with Propensity Score Matching
At a Glance
Category
Detail
Condition
Key Mechanisms
Dupilumab inhibits IL-4 and IL-13, key cytokines driving type 2 inflammation. [Source needed]
Target Population
Care Setting
Key Highlights
Dupilumab associated with reduced acute exacerbations at 6 and 12 months (RR 0.53 and 0.46).
Significant reduction in oral corticosteroid use (RR 0.67 and 0.66).
Increased risk of anaphylaxis in the dupilumab group (RR 1.80 and 1.74).
No significant differences in status asthmaticus, eosinophilia, or inpatient admissions.
Guideline-Based Recommendations
Diagnosis
Diagnosis relies on symptom patterns, risk profiles, and treatment response. [Source needed]
Management
Standard care includes low-dose inhaled corticosteroids for children <6 years. [Source needed]
Monitoring & Follow-up
Monitor for acute exacerbations, OCS use, and potential adverse effects. [Source needed]
Risks
Increased risk of anaphylaxis with dupilumab therapy. [Source needed]
Patient & Prescribing Data
Dupilumab provides clinical benefits alongside standard treatment. [Source needed]
Clinical Best Practices
Consider biologic agents for children with persistent asthma symptoms. [Source needed]
Follow GINA guidelines for asthma management in young children. [Source needed]
Pediatric migraine has historically been managed in fragments – symptoms recalled across months of episodic appointments. At Phoenix Children's, digital tools are reshaping care from episodic to continuous.
